CRISPR Therapeutics, ProBioGen to Develop In-Vivo Delivery Technologies
The companies will embark on a multi-year research collaboration to develop in-vivo delivery modalities for CRISPR/Cas9 by leveraging ProBioGen’s existing technology and expertise.
On Jan. 22, 2019, CRISPR Therapeutics, a biopharmaceutical company focused on creating gene-based medicines, and ProBioGen, a German service and technology provider, announced a multi-year research collaboration to develop in-vivo delivery modalities for CRISPR/Cas9 by leveraging ProBioGen’s existing technology and expertise.
“Our CRISPR/Cas9 platform has transformative potential across a broad range of devastating, genetically-defined diseases,” said Tony Ho, MD, executive vice-president, Research and Development at CRISPR Therapeutics, in a company press release. “To ensure we deliver on this potential, we continue to seek out pioneering new technologies and capabilities in support of our programs. We look forward to working with the ProBioGen team and leveraging their expertise to enhance our research and development efforts on in-vivo delivery of CRISPR/Cas9.”
Technical and financial details of the collaboration were not disclosed. The collaboration includes a license option for CRISPR Therapeutics upon successful completion of the research goals.
Source: CRISPR Therapeutics
